This page shows the latest Ovarian canncer news and features for those working in and with pharma, biotech and healthcare.
Cost watchdog wants more information for Lynparza. . NICE is once again saying no to AstraZeneca's new ovarian cancer drug - but is opening up a second consultation on its decision. ... The Institute is minded, in preliminary draft guidance, to reject
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...